REG - SkinBioTherapeutics - AxisBiotix-Ps™ to launch on Amazon UK

SkinbiotherapeuticsAnnouncement

30/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231130:nRSd1351Va&default-theme=true

RNS Number : 1351V  SkinBioTherapeutics PLC  30 November 2023

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

AxisBiotix-Ps™ to launch on Amazon UK

 

30 November 2023 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the
life science business focused on skin health announces that its
AxisBiotix-Ps™ food supplement will launch on Amazon.co.uk from Wednesday, 6
December 2023 at 9am.

 

The launch of a sales channel through Amazon is a key part of the
commercialisation strategy to expand market share for AxisBiotix-Ps™. The
first Amazon launch is in the UK; the aim is then to extend product
availability through other Amazon country sites. Management is already
proactively seeking to expand online sales of its AxisBiotix-Ps™ into the
European countries where the product has regulatory clearance (France, Italy
and Spain).

 

AxisBiotix-Ps™ first went on sale to UK in October 2021 and is intended for
customers to alleviate sensitive skin conditions such as psoriasis. The
response from customers continues to be very positive with the retention rates
of AxisBiotix-Ps™ in the UK staying at 80% or above. If access to the
product can be made simpler, via an online channel like Amazon which is
familiar to the majority of people, then management believes this will boost
sales and marketing efforts.

 

According to Mintel, approximately 90% of the UK adult population uses
Amazon. In 2019 alone, the UK e-commerce market was the largest in Europe and
third largest to China and the US. Amazon held 30% of this market, and has
shown ambitions in the beauty and skincare markets, with the launch of its
own-brand skin care line, Belei. It has also teamed up with beauty major,
L'Oreal.

 

Stuart J. Ashman, CEO of SkinBioTherapeutics, said: "The skin care market is
a significant market, with an increasing global focus on health and
well-being, and the demand for science-backed supplements is at an all-time
high. The primary focus for AxisBiotix-Ps™ is growing our share of the
market and using a sales channel like Amazon, which we use everyday, makes
good strategic sense. We hope to announce the European launches on Amazon
before the end of the year."

 

-Ends-

 

 For more information please contact:

SkinBioTherapeutics plc                            Tel: +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited                  Tel: +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Instinctif Partners (financial press)              Tel: +44 (0) 20 7457 2020

 Melanie Toyne-Sewell / Jack Kincade                SkinBioTherapeutics@instinctif.com

 Notes to Editors

 About SkinBioTherapeutics plc

 SkinBioTherapeutics is a life science company focused on skin health. The
 Company's proprietary platform technology, SkinBiotix®, is based upon
 discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

 The Company is targeting a number of skin healthcare sectors, the most
 advanced of which are cosmetic skincare and food supplements to modulate the
 immune system by harnessing the gut-skin axis. In each area
 SkinBioTherapeutics plans to exemplify its technology through human studies.
 The Company's first product, AxisBiotix-Ps™, a food supplement to address
 the symptoms of mild to moderate psoriasis.

 The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
 more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLDGBDBUXDDGXC